New-onset systemic sclerosis and scleroderma renal crisis under docetaxel. Issue 3 (October 2021)

• Record Type: Journal Article
• Authors: Debien, Véronique; Petitdemange, Arthur; Bazin, Dorothée; Ederle, Carole; Nespola, Benoit; Merdji, Hamid; Olagne, Jérome; Martin, Thierry; Guffroy, Aurélien; Pflumio, Carole
• Is Part Of: Journal of scleroderma and related disorders. Volume 6:Issue 3(2021)
• Page Start: 306
• Page End: 310
• Publication Date: 2021-10
• Subjects: Docetaxel -- chemotherapy -- scleroderma -- drug-induced autoimmune disease -- systemic sclerosis -- paraneoplastic; Scleroderma (Disease) -- Periodicals; Systemic scleroderma -- Periodicals; Fibrosis -- Periodicals; 616.544
• DOI: 10.1177/23971983211007669
• Languages: English
• ISSNs: 2397-1983

Abstract

Systemic sclerosis is a rare systemic autoimmune disease characterized by microvascular impairment and fibrosis of the skin and other organs with poor outcomes. Toxic causes may be involved. We reported the case of a 59-year-old woman who developed an acute systemic sclerosis after two doses of adjuvant chemotherapy by docetaxel and cyclophosphamide for a localized hormone receptor + human epithelial receptor 2—breast cancer. Docetaxel is a major chemotherapy drug used in the treatment of breast, lung, and prostate cancers, among others. Scleroderma-like skin-induced changes (morphea) have been already described for taxanes. Here, we report for the first time a case of severe lung and kidney flare with thrombotic microangiopathy after steroids for acute interstitial lung disease probably induced by anti-RNA polymerase III + systemic sclerosis after docetaxel.